Key Laboratory of Modern Acoustics (MOE), School of Physics, Nanjing University, Nanjing 210093, China.
The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Ultrason Sonochem. 2019 May;53:178-186. doi: 10.1016/j.ultsonch.2019.01.005. Epub 2019 Jan 7.
Microbubble-mediated sonoporation is a promising strategy for intracellular gene/drug delivery, but the biophysical mechanisms involved in the interactions between microbubbles and cells are not well understood. Here, HeLa cells were synchronized in individual cycle phases, then the cell-cycle-dependences of the membrane permeability and viability of HeLa cells undergoing multi-bubble sonoporation were evaluated using focused ultrasound exposure apparatus coupled passive cavitation detection system. The results indicated that: (1) the microbubble cavitation activity should be independent on cell cycle phases; (2) G-phase cells with the largest Young's modulus were the most robust against microbubble-mediated sonoporation; (3) G/M-phase cells exhibited the greatest accumulated FITC uptake with the lowest viability, which should be mainly attributed to the chemical effect of synchronization drugs; and (4) more important, S-phase cells with the lowest stiffness seemed to be the most susceptible to the mechanical effect generated by microbubble cavitation activity, which resulted in the greatest enhancement in sonoporation-facilitated membrane permeabilization without further scarifying their viability. The current findings may benefit ongoing efforts aiming to pursue rational utilization of microbubble-mediated sonoporation in cell-cycle-targeted gene/drug delivery for cancer therapy.
超声空化微泡转染是一种很有前途的细胞内基因/药物传递策略,但微泡与细胞相互作用的生物物理机制还不是很清楚。在这里,通过使用聚焦超声暴露装置和被动空化检测系统,将 HeLa 细胞在单个细胞周期阶段同步化,然后评估多泡超声转染过程中 HeLa 细胞的细胞膜通透性和活力的细胞周期依赖性。结果表明:(1)微泡空化活性应独立于细胞周期阶段;(2)杨氏模量最大的 G 期细胞对微泡介导的超声转染最具抵抗力;(3)G/M 期细胞表现出最大的累积 FITC 摄取和最低的活力,这主要归因于同步化药物的化学效应;(4)更重要的是,杨氏模量最低的 S 期细胞似乎最容易受到微泡空化活性产生的机械效应的影响,这导致了超声转染促进的膜通透性的最大增强,而不会进一步损害其活力。目前的研究结果可能有助于正在进行的努力,旨在将超声空化微泡转染用于癌症治疗的细胞周期靶向基因/药物传递,以实现合理利用。